Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414992 | 0.79 | CES2 (0.58) | CES2P2RX1GAA | |
| SCHEMBL2095433 | 0.79 | CES2 (0.58) | CES2P2RX1GAA | |
| SCHEMBL6220956 | 0.77 | NR4A1 (0.53) | CES2NR4A1NR4A2NR4A3 | |
| SCHEMBL2092820 | 0.77 | NR4A1 (0.53) | CES2NR4A1NR4A2NR4A3 | |
| SCHEMBL18380964 | 0.76 | CES2 (0.50) | CES2RXRARXRBRXRGNOTUM | |
| SCHEMBL14471508 | 0.75 | CES2 (0.61) | CES2RXRARXRBRXRGTACR1 | |
| SCHEMBL13984577 | 0.73 | CES2 (0.58) | CES2RXRARXRBRXRGTACR1 | |
| SCHEMBL15561973 | 0.73 | CES2 (0.58) | CES2RXRARXRBRXRGTACR1 | |
| SCHEMBL25615569 | 0.72 | CES2 (0.42) | CES2RXRARXRBRXRGTACR1 | |
| SCHEMBL20849511 | 0.72 | CES2 (0.47) | CES2RXRARXRBRXRGTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1765780-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006004195-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CES2 2243/4885RXRA 179/4885RXRB 138/4885 |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | AVPR1B, HRH4, PRLHR | CES2 3515/4885RXRA 1379/4885RXRB 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.